Live Breaking News & Updates on Ibi351 Monotherapy

Stay updated with breaking news from Ibi351 monotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

IBI351 Receives Breakthrough Therapy Designation in China for Previously Treated Advanced CRC

China’s National Medical Products Administration has granted a breakthrough therapy designation to the KRAS G12C inhibitor IBI351 as monotherapy for previously treated patients with advanced colorectal carcinoma harboring a KRAS G12C mutation. ....

Rhui Zhou , China National Medical Products Administration , National Medical Products Administration , Ibi351 , Patients With Advanced Colorectal Carcinoma , Ibi351 Monotherapy , Patients With Advanced Nsclc And Gastrointestinal Tumors ,